Absci (ABSI) Debt Ratio (2020 - 2026)

Absci (ABSI) posted Debt Ratio of 0.05 for Q3 2025, down 14.96% sequentially from 0.06 in Q2 2025, and up 470.97% YoY from 0.01 in Q3 2024.

Analysis

Absci (ABSI) Debt Ratio (2020 - 2026) Analysis & Trends

Absci has reported Debt Ratio for 6 years, with the latest figure at 0.05 in Q3 2025.

Quarterly Debt Ratio rose 470.97% year-over-year to 0.05 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 0.05 (up 470.97% YoY) and the FY2024 annual result came in at 0.07, down 18.16% from the prior year.
Debt Ratio eased to 0.05 in Q3 2025 per ABSI's latest filing, from 0.06 in the prior quarter.
Over five years, Debt Ratio peaked at 0.08 in Q4 2023 and troughed at 0.0 in Q1 2022.
A 5-year average of 0.03 and a median of 0.02 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2021 and 2023: Debt Ratio slumped 95.11% in 2021, then jumped 1710.2% in 2023.
Over 5 years, Debt Ratio stood at 0.0 in 2021, then jumped by 843.08% to 0.02 in 2022, then soared by 222.14% to 0.08 in 2023, then fell by 18.16% to 0.07 in 2024, then retreated by 20.23% to 0.05 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.05, 0.06, and 0.06 for Q3 2025, Q2 2025, and Q1 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Absci	1.39 Bn	1.19 Bn	-	0.00

Historic Data

Download Data